Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

147 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Reply to B. Zhao et al.
Polley MC, Gorlia T, Lassman AB, van den Bent MJ. Polley MC, et al. Among authors: lassman ab. J Clin Oncol. 2023 Feb 1;41(4):934-935. doi: 10.1200/JCO.22.01874. Epub 2022 Oct 3. J Clin Oncol. 2023. PMID: 36191279 No abstract available.
Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group.
Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, Degroot J, Wick W, Gilbert MR, Lassman AB, Tsien C, Mikkelsen T, Wong ET, Chamberlain MC, Stupp R, Lamborn KR, Vogelbaum MA, van den Bent MJ, Chang SM. Wen PY, et al. Among authors: lassman ab. J Clin Oncol. 2010 Apr 10;28(11):1963-72. doi: 10.1200/JCO.2009.26.3541. Epub 2010 Mar 15. J Clin Oncol. 2010. PMID: 20231676
Clinical trial end points for high-grade glioma: the evolving landscape.
Reardon DA, Galanis E, DeGroot JF, Cloughesy TF, Wefel JS, Lamborn KR, Lassman AB, Gilbert MR, Sampson JH, Wick W, Chamberlain MC, Macdonald DR, Mehta MP, Vogelbaum MA, Chang SM, Van den Bent MJ, Wen PY. Reardon DA, et al. Among authors: lassman ab. Neuro Oncol. 2011 Mar;13(3):353-61. doi: 10.1093/neuonc/noq203. Epub 2011 Feb 9. Neuro Oncol. 2011. PMID: 21310734 Free PMC article. Review.
Efficacy and safety results of ABT-414 in combination with radiation and temozolomide in newly diagnosed glioblastoma.
Reardon DA, Lassman AB, van den Bent M, Kumthekar P, Merrell R, Scott AM, Fichtel L, Sulman EP, Gomez E, Fischer J, Lee HJ, Munasinghe W, Xiong H, Mandich H, Roberts-Rapp L, Ansell P, Holen KD, Gan HK. Reardon DA, et al. Among authors: lassman ab. Neuro Oncol. 2017 Jul 1;19(7):965-975. doi: 10.1093/neuonc/now257. Neuro Oncol. 2017. PMID: 28039367 Free PMC article. Clinical Trial.
Efficacy of depatuxizumab mafodotin (ABT-414) monotherapy in patients with EGFR-amplified, recurrent glioblastoma: results from a multi-center, international study.
van den Bent M, Gan HK, Lassman AB, Kumthekar P, Merrell R, Butowski N, Lwin Z, Mikkelsen T, Nabors LB, Papadopoulos KP, Penas-Prado M, Simes J, Wheeler H, Walbert T, Scott AM, Gomez E, Lee HJ, Roberts-Rapp L, Xiong H, Bain E, Ansell PJ, Holen KD, Maag D, Reardon DA. van den Bent M, et al. Among authors: lassman ab. Cancer Chemother Pharmacol. 2017 Dec;80(6):1209-1217. doi: 10.1007/s00280-017-3451-1. Epub 2017 Oct 26. Cancer Chemother Pharmacol. 2017. PMID: 29075855 Free PMC article. Clinical Trial.
Safety, pharmacokinetics, and antitumor response of depatuxizumab mafodotin as monotherapy or in combination with temozolomide in patients with glioblastoma.
Gan HK, Reardon DA, Lassman AB, Merrell R, van den Bent M, Butowski N, Lwin Z, Wheeler H, Fichtel L, Scott AM, Gomez EJ, Fischer J, Mandich H, Xiong H, Lee HJ, Munasinghe WP, Roberts-Rapp LA, Ansell PJ, Holen KD, Kumthekar P. Gan HK, et al. Among authors: lassman ab. Neuro Oncol. 2018 May 18;20(6):838-847. doi: 10.1093/neuonc/nox202. Neuro Oncol. 2018. PMID: 29077941 Free PMC article. Clinical Trial.
Clinical trial design for systemic agents in patients with brain metastases from solid tumours: a guideline by the Response Assessment in Neuro-Oncology Brain Metastases working group.
Camidge DR, Lee EQ, Lin NU, Margolin K, Ahluwalia MS, Bendszus M, Chang SM, Dancey J, de Vries EGE, Harris GJ, Hodi FS, Lassman AB, Macdonald DR, Peereboom DM, Schiff D, Soffietti R, van den Bent MJ, Wefel JS, Wen PY. Camidge DR, et al. Among authors: lassman ab. Lancet Oncol. 2018 Jan;19(1):e20-e32. doi: 10.1016/S1470-2045(17)30693-9. Lancet Oncol. 2018. PMID: 29304358 Review.
Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with EGFR-amplified, recurrent glioblastoma: results from an international phase I multicenter trial.
Lassman AB, van den Bent MJ, Gan HK, Reardon DA, Kumthekar P, Butowski N, Lwin Z, Mikkelsen T, Nabors LB, Papadopoulos KP, Penas-Prado M, Simes J, Wheeler H, Walbert T, Scott AM, Gomez E, Lee HJ, Roberts-Rapp L, Xiong H, Ansell PJ, Bain E, Holen KD, Maag D, Merrell R. Lassman AB, et al. Neuro Oncol. 2019 Jan 1;21(1):106-114. doi: 10.1093/neuonc/noy091. Neuro Oncol. 2019. PMID: 29982805 Free PMC article. Clinical Trial.
Comparison of Biomarker Assays for EGFR: Implications for Precision Medicine in Patients with Glioblastoma.
Lassman AB, Roberts-Rapp L, Sokolova I, Song M, Pestova E, Kular R, Mullen C, Zha Z, Lu X, Gomez E, Bhathena A, Maag D, Kumthekar P, Gan HK, Scott AM, Guseva M, Holen KD, Ansell PJ, van den Bent MJ. Lassman AB, et al. Clin Cancer Res. 2019 Jun 1;25(11):3259-3265. doi: 10.1158/1078-0432.CCR-18-3034. Epub 2019 Feb 22. Clin Cancer Res. 2019. PMID: 30796037 Free PMC article.
147 results